Nascent Biotech, Inc. (NBIO)
OTCMKTS · Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
Sep 4, 2026, 4:00 PM EST
Nascent Biotech Balance Sheet
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
Cash & Equivalents | 0.05 | 0.37 | 0.17 | 0.09 | 0 | 0 |
Cash & Short-Term Investments | 0.05 | 0.37 | 0.17 | 0.09 | 0 | 0 |
Cash Growth | 399.90% | 116.11% | 82.37% | 6479.37% | -55.41% | -97.55% |
Receivables | - | - | - | - | 0.75 | - |
Prepaid Expenses | 0.18 | 0.18 | 0.08 | 0.01 | - | - |
Total Current Assets | 0.23 | 0.55 | 0.26 | 0.11 | 0.75 | 0 |
Total Assets | 0.23 | 0.55 | 0.26 | 0.11 | 0.75 | 0 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
Accounts Payable | 0.68 | 0.69 | 0.5 | 0.78 | 0.64 | 0.85 |
Accrued Expenses | - | - | - | - | - | 1.28 |
Short-Term Debt | 0.06 | 0.12 | 0.39 | - | 0.16 | 0.14 |
Other Current Liabilities | - | - | 0.66 | - | 0.43 | 0.6 |
Total Current Liabilities | 0.74 | 0.81 | 1.55 | 0.78 | 1.22 | 2.88 |
Total Liabilities | 0.74 | 0.81 | 1.55 | 0.78 | 1.22 | 2.88 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
Common Stock | 0.17 | 0.17 | 0.13 | 0.11 | 0.1 | 0.04 |
Additional Paid-In Capital | 23.95 | 23.83 | 20.19 | 18.04 | 17.77 | 13.92 |
Retained Earnings | -24.64 | -24.26 | -21.62 | -18.82 | -18.35 | -16.84 |
Total Common Equity | -0.51 | -0.26 | -1.3 | -0.67 | -0.47 | -2.88 |
Shareholders' Equity | -0.51 | -0.26 | -1.3 | -0.67 | -0.47 | -2.88 |
Total Liabilities & Equity | 0.23 | 0.55 | 0.26 | 0.11 | 0.75 | 0 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
Total Debt | 0.06 | 0.12 | 0.39 | - | 0.16 | 0.14 |
Net Cash (Debt) | -0.01 | 0.25 | -0.22 | 0.09 | -0.16 | -0.14 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.00 | 0.00 | -0.00 | 0.00 | -0.00 | -0.00 |
Filing Date Shares Outstanding | 172.2 | 172.2 | 141.4 | 115.01 | 107.73 | 48.27 |
Total Common Shares Outstanding | 172.2 | 170.59 | 131.76 | 111.31 | 104.83 | 44.89 |
Working Capital | -0.51 | -0.26 | -1.3 | -0.67 | -0.47 | -2.88 |
Book Value Per Share | -0.00 | -0.00 | -0.01 | -0.01 | -0.00 | -0.06 |
Tangible Book Value | -0.51 | -0.26 | -1.3 | -0.67 | -0.47 | -2.88 |
Tangible Book Value Per Share | -0.00 | -0.00 | -0.01 | -0.01 | -0.00 | -0.06 |